A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, cell, circulating, CTC, expression, liquid, PTEN, tumor | 2 Comments »
A new paper by Cuzick and colleagues has suggested that loss of expression of the PTEN gene, which encodes for a protein known as phosphatase and tensin homologue (PTEN), may be significantly associated with heightened risk of progressive disease in a cohort of nominally low-risk patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, expression, outcome, PTEN, risk, Treatment | Leave a comment »
A new study, to published shortly on-line in Cancer, suggests that significant alterations to the “copy numbers” of the PTEN and MYC genes in men with prostate cancer are strongly associated with risk for prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: alteration, analysis, copy number, gene, mortality, MYC, PTEN, risk | 3 Comments »
A new report from members of the Transatlantic Prostate Study Group has suggested that information about three specific genes may be sufficient to identify a high proportion of men with potentially lethal as opposed to indolent prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ERG/ETV1, gene loss, gene rearrangement, prognosis, PTEN, survival | 5 Comments »
Today’s news reports cover items on:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biopsy, CRPC, ERG, expression, gene, IMRT, PTEN, RALP, side effects, toxicity, urinary, voiding | Leave a comment »
